Radius Health Inc (RDUS)

34.93
NASDAQ : Health Care
Prev Close 36.20
Day Low/High 34.79 / 36.20
52 Wk Low/High 31.58 / 59.88
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 43.38M
Market Cap 1.57B
EPS -4.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of RDUS January 2018 Options Trading

Investors in Radius Health Inc saw new options become available this week, for the January 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Jim Cramer: Radius Health Is a Takeover Target

Jim Cramer: Radius Health Is a Takeover Target

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said Radius Health is a takeover target.

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.

Biotech Movers: Radius Health, Amgen, Paratek

Biotech Movers: Radius Health, Amgen, Paratek

Radius Health, Amgen and Paratek Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Six Flags, Cara Therapeutics, Hertz Global Holdings: 'Mad Money' Lightning Round

Six Flags, Cara Therapeutics, Hertz Global Holdings: 'Mad Money' Lightning Round

Jim Cramer is bullish on Six Flags and Cara Therapeutics, but he's bearish on General Motors and Pandora.

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Jim Cramer says he's amazed that stocks -- and gold, even -- are just yawning at Trump's move to fire FBI Director Comey.

Insiders Are Loading Up on Twitter, Biogen & More

Insiders Are Loading Up on Twitter, Biogen & More

Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately.

Radius Health Stock Sees Short Interest Increase 10.2%

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 734,672 share increase in total short interest for Radius Health Inc , to 7,898,852, an increase of 10.25% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week Of May 19th Options Trading For Radius Health (RDUS)

Investors in Radius Health Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RDUS options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at Herbalife, Chesapeake Energy and three other companies have been scooping up shares of their own stock lately.

Radius Health Receives Notification Of PDUFA Extension For Abaloparatide-SC

PDUFA goal date extended by standard extension period of three months to June 30, 2017

Interesting RDUS Put And Call Options For March 17th

Interesting RDUS Put And Call Options For March 17th

Investors in Radius Health Inc saw new options become available this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RDUS options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

'Mad Money' Lightning Round: Take Citi Over CIT Group

'Mad Money' Lightning Round: Take Citi Over CIT Group

Cramer says P&G is a good choice and is disappointed by Bristol-Myers Squibb.